通过单克隆抗体对突变的人类胰岛素受体的功能激活
1Department of Medicine, University of Cambridge, Addenbrooke's Hospital, UK.
Lancet (London, England)
|June 8, 1996
概括
一种新型单克隆抗体可以激活Rabson-Mendenhall综合征中的突变胰岛素受体 (Ser323Leu),绕过缺陷的胰岛素结合并恢复潜在治疗应用的胰岛素信号通路.
科学领域:
- 分子内分泌学分子内分泌学
- 蜂信号传输是如何进行的
- 受体生物学受体生物学
背景情况:
- 拉布森-门登霍尔综合征的特征是由于突变胰岛素受体 (Ser323Leu) 的严重胰岛素抵抗.
- 该SER323Leu突变损害了胰岛素结合亲和力,使传统疗法变得无效.
- 一个单克隆抗体 (83.14) 针对胰岛素受体的细胞外域,可能模仿胰岛素的初始信号效应.
研究的目的:
- 调查单克隆抗体83.14是否可以激活Ser323Leu突变胰岛素受体.
- 为了确定抗体诱导的激活是否可以恢复下游信号和代谢效应.
主要方法:
- 对中国仓鼠卵巢细胞中野生型和突变型胰岛素受体的胰岛素和抗体作用的比较.
- 试验包括受体自酸化和糖原合成测量.
主要成果:
- 具有SER323Leu突变受体的细胞显示了最小的胰岛素结合,自酸化和糖原合成.
- 暴露于单克隆抗体83.14诱导了突变受体细胞的自化和糖原合成,类似于野生型受体.
结论:
- 单克隆抗体83.14通过激活Ser323Leu突变胰岛素受体,有效地模仿胰岛素信号传递.
- 这种抗体介导的激活为遗传性激素耐药性疾病提供了潜在的治疗策略,这种疾病具有缺陷的连接体结合.
相关概念视频
Hybridoma Technology
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
Insulin: The Receptor and Signaling Pathways
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but this inhibition is released...
Insulin: Biosynthesis, Chemistry, and Preparation
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...
Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Production of Pharmaceuticals
Industrial insulin production uses genetically engineered E. coli expressing a proinsulin gene controlled by a tryptophan promoter and containing a methionine linker for later cleavage. The cells also carry ampicillin resistance for selective growth. Seed cultures are stored at −80 °C and production begins by thawing a small amount to inoculate starter cultures, which are progressively scaled to a 50,000-L bioreactor. In the bioreactor, E. coli grow in nutrient-rich media under sterile, tightly...


